Compositions of matter and pharmaceutical compositions
Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.
1. A compound of the formula of Structure (1):
wherein:
X is CF 3 , or a halogen selected from the group consisting of Cl, Br, I, and astatine;
R 1 consists of an aliphatic substituent with a primary, secondary, tertiary, or quaternary amine; and
R 2 is hydroxyl, an ester, an ether, an aldehyde, an acid, an amide, a thiol, a sulfone, a sulfonamide or combinations thereof.
2. The compound of claim 1 , wherein R 1 is a tertiary amine.
3. The compound of claim 1 , wherein X is Cl, Br, or I.
4. The compound of claim 2 , wherein X is Cl, Br, or I.
5. The compound of claim 1 , wherein R 2 is an ester.
6. The compound of claim 2 , wherein R 2 is an ester.
7. The compound of claim 3 , wherein R 2 is an ester.
8. The compound of claim 4 , wherein R 2 is an ester.
9. The compound of claim 5 , wherein the ester is an acetate ester.
10. The compound of claim 6 , wherein the ester is an acetate ester.
11. The compound of claim 7 , wherein the ester is an acetate ester.
12. The compound of claim 8 , wherein the ester is an acetate ester.
13. A compound of the formula of Structure (1):
wherein:
X is Br;
R 1 consists of an aliphatic substituent with a primary, secondary, tertiary, or quaternary amine; and
R 2 is hydroxyl, an ester, an ether, an aldehyde, an acid, an amide, a thiol, a sulfone, a sulfonamide or combinations thereof.
14. The compound of claim 2 , wherein X is Br.
15. The compound of claim 5 , wherein X is Br.
16. The compound of claim 6 , wherein X is Br.
17. The compound of claim 9 , wherein X is Br.
18. The compound of claim 10 , wherein X is Br.
19. The compound of claim 1 , wherein the composition has the following structure: